Trial · NCT02413008
Outcomes16
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Variation in Serum Levels of Follicle Stimulating Hormone (FSH) | from baseline to 12 weeks of treatment | postmenopausal participants | mIU/ml | MEDIAN |
| SECONDARY | Variation in Serum Levels of FSH at Week 1, Week 3 and Week 8 | Change from baseline to week 1, week 3 and week 8 | postmenopausal women | mIU/ml | MEAN |
| SECONDARY | Variation in Serum Levels of Luteinizing Hormone (LH) | Change from baseline to week 1, week 3, week 8 and week 12 | postmenopausal women | mIU/ml | MEDIAN |
| SECONDARY | Variation in Plasma Levels of Estriol | Change from baseline to week 1, week 3, week 8 and week 12 | postmenopausal women | pg/mL | MEDIAN |
| SECONDARY | Variation in Plasma Levels of Estradiol | Change from baseline to week 1, week 3, week 8 and week 12 | postmenopausal women | pg/mL | MEDIAN |
| SECONDARY | Variation in Plasma Levels of Estrona | Change from baseline to week 1, week 3, week 8 and week 12 | postmenopausal women | pg/mL | MEDIAN |
| SECONDARY | Changes in Vaginal pH Between Baseline and Week 3 and Week 12 | week 3 and week 12 vs baseline | postmenopausal women | units on a scale | MEAN |
| SECONDARY | Changes in Dyspareunia | week 3 and week 12 vs baseline | postmenopausal women | score on a scale | MEDIAN |
| SECONDARY | Change in Pruritus or Itching From Baseline to Week 3 and Week 12 | Change from baseline to week 3 and week 12 | postmenopausal women | units on a scale | MEDIAN |
| SECONDARY | Changes in Vaginal Dryness | week 3 and week 12 vs baseline | postmenopausal women | units on a scale | MEDIAN |
| SECONDARY | Changes in Total Score of Symptoms of Vaginal Atrophy | week 3 and week 12 vs baseline | postmenopausal women | score on a scale | MEDIAN |
| SECONDARY | Changes in Dryness of the Mucosa | week 3 and week 12 vs baseline | postmenopausal women | score on a scale | MEDIAN |
| SECONDARY | Changes in Fragility of the Mucosa [Time Frame: Week 3 and Week 12 vs Baseline] | from baseline to week 3 and 12 | Postmenopausal women | score on a scale | MEDIAN |
| SECONDARY | Changes in Vaginal Mucosa With Flattening of Folds or Thinning | week 3 and week 12 vs baseline | postmenopausal women | score on a scale | MEDIAN |
| SECONDARY | Changes in Total Score of Signs of Vaginal Atrophy Between Week 3 and Week 12 to Baseline | week 3 and week 12 vs baseline | postmenopausal women | score on a scale | MEDIAN |
| SECONDARY | Changes in Vaginal Maturation Value | week 3 and week 12 vs baseline | postmenopausal women | % of cells | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02413008/outcomes